Study of IRIS for Infants and Children Initiating HAART at Int'l Sites (P1073-IRIS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT01240486
First received: November 11, 2010
Last updated: July 1, 2013
Last verified: July 2013

November 11, 2010
July 1, 2013
November 2010
February 2013   (final data collection date for primary outcome measure)
  • Proportion of study subjects having BCG-related IRIS within 48 weeks of initiating HAART. [ Time Frame: within 48 weeks of iniating HAART ] [ Designated as safety issue: No ]
  • Proportion of study subjects having unmasking and paradoxical TB-related IRIS within 48 weeks of initiating HAART. [ Time Frame: Within 48 weeks of initiating HAART ] [ Designated as safety issue: No ]
  • Nadir CD4 T-cell count and percentage and plasma viral load pre-HAART initiation, and two weeks post-HAART and CD4 T-cell count and percentage and plasma viral load at the presumptive BCG or TB-IRIS event, for CASES and the matching controls. [ Time Frame: At Study Entry, 2 weeks post-HAART and within 48 weeks of initiating HAART ] [ Designated as safety issue: No ]
  • CD4 T-cell count and percentage and plasma viral load, 48 weeks post-HAART initiation for CASES and the matching controls. [ Time Frame: 48 weeks post-HAART ] [ Designated as safety issue: No ]
  • Frequency of all IRIS-like events and proportion attributed to BCG or TB. [ Time Frame: within 48 weeks of initiating HAART ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT01240486 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of IRIS for Infants and Children Initiating HAART at Int'l Sites
Study Of Immune Reconstitution Inflammatory Syndrome (IRIS) For International Sites Initiating Highly Active Antiretroviral Therapy (HAART) In Infants And Children < 72 Months Of Age

Your child is able to participate in this study, if your child's doctor is planning to start your child on HAART (which is a combination of at least 3 anti HIV drugs). When your child is treated with HAART, the way your child's body is able to fight infection may change. The immune system is the body's defense against infection. Your child's immune system may respond in a stronger way to some types of infections that your child may already have. This immune response may cause your child to become sick and the condition is then called "immune reconstitution inflammatory syndrome" or IRIS.

P1073 is a prospective clinical, observational and pathogenesis study of HIV-infected infants and children who are ART-naïve and will be initiating a HAART regimen at an IMPAACT study site. Where possible, infants and children co-enrolled in IMPAACT studies will be given preference for enrollment in P1073.

The plan is to enroll subjects in P1073 at a timepoint ≤ 1 week prior to starting HAART. For DMC purposes, this is Step 1 for P1073, and subjects are designated as a Non-case, according to the Study Flow Chart

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

This is a prospective, clinical observational and pathogenesis study of HIV-infected infants and children stratified into 2 age groups: ≥ 4 weeks to ≤ 12 months of age; and > 12 to < 72 months of age who will enroll into P1073 at a timepoint ≤ 1 week prior to initiating HAART

  • IRIS
  • HIV
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
500
April 2016
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Past or current documentation of a confirmed diagnosis of HIV-1 infection. Documentation of HIV-1 infection is defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma.

    • Sample #1 may be tested by non-study public or PEPFAR programs. However, both the result and the assay date must be recorded in subject's chart. Source documentation (patient's medical record/chart, Ministry of Health (MOH) registers, laboratory results, etc.) must be available if requested.
    • Sample #2 must be performed in a CAP/CLIA-approved laboratory (for US sites) or in a laboratory that operates according to GCLP guidelines and participates in an appropriate external quality assurance program (for international sites).
    • For P1073, the subject may be enrolled before the result of Sample #2 is available. However, the subject will be taken off study should the 2nd result be negative.

      1. Acceptable tests when subjects are ≤ 18 months of age

        1. Sample #1 may be tested using any of the following: One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL); One qualitative HIV RNA PCR; One total HIV nucleic acid test

          **If Sample #1 is positive, collect and test Sample #2.

        2. Sample #2 may be tested using any of the assays listed above for Sample #1.
      2. Acceptable tests when subjects are > 18 months of age

        1. Sample #1 may be tested using any of the following: Two rapid antibody tests from different manufacturers or based on different principles and epitopes; One EIA OR Western Blot OR immunofluorescence OR chemiluminescence; One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL; One qualitative HIV RNA PCR; One HIV culture (prior to August 2009); One total HIV nucleic acid test

          **If Sample #1 is positive, then collect and test Sample #2.

        2. Sample #2 may be tested using any of the following: One EIA confirmed by Western Blot OR immunofluorescence OR chemiluminescence; One HIV DNA PCR; One quantitative HIV RNA PCR (>5,000 copies/mL); One qualitative HIV RNA PCR; One HIV culture (prior to August 2009;)One total HIV nucleic acid test

          • Rapid antibody tests are not allowed for sample #2
  • Age: range is ≥ 4 weeks to < 72 months of age at time of HAART initiation.

    *All infants and children ≥ 4 weeks to < 72 months of age, who are about to initiate HAART according to National or WHO criteria, are eligible.

  • HIV-infected infants and children who meet the ART guidelines of local programs or an IMPAACT or other protocol and who can be enrolled ≤ 1 week prior to starting HAART.
  • No known active untreated opportunistic infection.
  • Infants ≤ 12 months of age should have received BCG immunization and the date of BCG vaccine has to be known.
  • Legal guardian able and willing to provide signed informed consent for participating in the IRIS study.

Exclusion Criteria

-Any clinically significant diseases (other than HIV infection) e.g. malignancy, auto-immune or inflammatory diseases requiring long-term immunosuppressive therapy, or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise the outcome of this study. Please contact the team at actg.teamp1073@fstrf.org.

Both
up to 72 Months
No
Contact information is only displayed when the study is recruiting subjects
India,   South Africa,   Tanzania,   Uganda,   Zimbabwe
 
NCT01240486
P1073, U01AI068632
No
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study Chair: Mark Cotton, MD IMPAACT/Stellenbosch University
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP